Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 68
Filtrar
1.
Mem Inst Oswaldo Cruz ; 115: e190389, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32074167

RESUMO

BACKGROUND: Chagas disease, which is caused by the protozoan Trypanosoma cruzi, is endemic to Latin America and mainly affects low-income populations. Chemotherapy is based on two nitrocompounds, but their reduced efficacy encourages the continuous search for alternative drugs. Our group has characterised the trypanocidal effect of naphthoquinones and their derivatives, with naphthoimidazoles derived from ß-lapachone (N1, N2 and N3) being the most active in vitro. OBJECTIVES: In the present work, the effects of N1, N2 and N3 on acutely infected mice were investigated. METHODS: in vivo activity of the compounds was assessed by parasitological, biochemical, histopathological, immunophenotypical, electrocardiographic (ECG) and behavioral analyses. FINDINGS: Naphthoimidazoles led to a decrease in parasitaemia (8 dpi) by reducing the number of bloodstream trypomastigotes by 25-50% but not by reducing mortality. N1 protected mice from heart injury (15 dpi) by decreasing inflammation. Bradycardia was also partially reversed after treatment with N1 and N2. Furthermore, the three compounds did not reverse hepatic and renal lesions or promote the improvement of other evaluated parameters. MAIN CONCLUSION: N1 showed moderate trypanocidal and promising immunomodulatory activities, and its use in combination with benznidazole and/or anti-arrhythmic drugs as well as the efficacy of its alternative formulations must be investigated in the near future.


Assuntos
Doença de Chagas/tratamento farmacológico , Naftoquinonas/uso terapêutico , Nitroimidazóis/uso terapêutico , Tripanossomicidas/uso terapêutico , Doença Aguda , Animais , Anti-Inflamatórios , Modelos Animais de Doenças , Eletrocardiografia , Masculino , Camundongos , Naftoquinonas/química , Nitroimidazóis/química , Parasitemia/tratamento farmacológico , Fatores de Tempo , Tripanossomicidas/química
2.
Mem Inst Oswaldo Cruz ; 110(4): 492-9, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26018452

RESUMO

Nitroimidazoles exhibit high microbicidal activity, but mutagenic, genotoxic and cytotoxic properties have been attributed to the presence of the nitro group. However, we synthesised nitroimidazoles with activity against the trypomastigotes of Trypanosoma cruzi, but that were not genotoxic. Herein, nitroimidazoles (11-19) bearing different substituent groups were investigated for their potential induction of genotoxicity (comet assay) and mutagenicity (Salmonella/Microsome assay) and the correlations of these effects with their trypanocidal effect and with megazol were investigated. The compounds were designed to analyse the role played by the position of the nitro group in the imidazole nucleus (C-4 or C-5) and the presence of oxidisable groups at N-1 as an anion receptor group and the role of a methyl group at C-2. Nitroimidazoles bearing NO2 at C-4 and CH3 at C-2 were not genotoxic compared to those bearing NO 2 at C-5. However, when there was a CH3 at C-2, the position of the NO2 group had no influence on the genotoxic activity. Fluorinated compounds exhibited higher genotoxicity regardless of the presence of CH3 at C-2 or NO2 at C-4 or C-5. However, in compounds 11 (2-CH3; 4-NO2; N-CH2OHCH2Cl) and 12 (2-CH3; 4-NO2; N-CH2OHCH2F), the fluorine atom had no influence on genotoxicity. This study contributes to the future search for new and safer prototypes and provide.


Assuntos
Dano ao DNA/efeitos dos fármacos , Nitroimidazóis/química , Nitroimidazóis/toxicidade , Salmonella/efeitos dos fármacos , Trypanosoma cruzi/efeitos dos fármacos , Animais , Ensaio Cometa , Relação Dose-Resposta a Droga , Camundongos , Testes de Mutagenicidade , Relação Estrutura-Atividade
5.
Mem. Inst. Oswaldo Cruz ; 110(4): 492-499, 09/06/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-748858

RESUMO

Nitroimidazoles exhibit high microbicidal activity, but mutagenic, genotoxic and cytotoxic properties have been attributed to the presence of the nitro group. However, we synthesised nitroimidazoles with activity against the trypomastigotes of Trypanosoma cruzi, but that were not genotoxic. Herein, nitroimidazoles (11-19) bearing different substituent groups were investigated for their potential induction of genotoxicity (comet assay) and mutagenicity (Salmonella/Microsome assay) and the correlations of these effects with their trypanocidal effect and with megazol were investigated. The compounds were designed to analyse the role played by the position of the nitro group in the imidazole nucleus (C-4 or C-5) and the presence of oxidisable groups at N-1 as an anion receptor group and the role of a methyl group at C-2. Nitroimidazoles bearing NO2 at C-4 and CH3 at C-2 were not genotoxic compared to those bearing NO 2 at C-5. However, when there was a CH3 at C-2, the position of the NO2 group had no influence on the genotoxic activity. Fluorinated compounds exhibited higher genotoxicity regardless of the presence of CH3 at C-2 or NO2 at C-4 or C-5. However, in compounds 11 (2-CH3; 4-NO2; N-CH2OHCH2Cl) and 12 (2-CH3; 4-NO2; N-CH2OHCH2F), the fluorine atom had no influence on genotoxicity. This study contributes to the future search for new and safer prototypes and provide.


Assuntos
Animais , Camundongos , Dano ao DNA/efeitos dos fármacos , Nitroimidazóis/química , Nitroimidazóis/toxicidade , Salmonella/efeitos dos fármacos , Trypanosoma cruzi/efeitos dos fármacos , Ensaio Cometa , Relação Dose-Resposta a Droga , Testes de Mutagenicidade , Relação Estrutura-Atividade
7.
Artigo em Inglês | Arca: Repositório institucional da Fiocruz | ID: arc-12387

RESUMO

A doença de Chagas causada pelo Trypanosoma cruzi afeta cerca de oito milhões de pessoas em países em desenvolvimento, sendo classificada como uma doença tropical negligenciada pela Organização Mundial da Saúde. A quimioterapia disponível para esta doença é baseada em dois nitro-heterocíclicos, nifurtimox e benznidazol, ambos com graves efeitos colaterais e eficácia variável, e assim novos medicamentos visando um tratamento mais eficiente são necessários com urgência. Nos últimos 20 anos, temos desenvolvido em colaboração com grupos focados em química medicinal, um programa de quimioterapia experimental da doença de Chagas, investigando a eficácia, seletividade, toxicidade, alvos celulares e mecanismos de ação de diferentes classes de compostos sobre T. cruzi. Neste artigo, apresentamos uma visão geral desses estudos, enfocando protótipos naftoquinoidais e derivados, examinando a sua síntese, a atividade e mecanismo de ação, o que foi realizado e o que precisa ser abordado, avaliando e discutindo possíveis melhorias. Esta mini-revisão discute nosso esforço continuado visando a caracterização biológica e a síntese de compostos naftoquinoidais, auxiliando no desenvolvimento de um novo arsenal de drogas candidatas com eficácia contra o T. cruzi.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA